Pharmaron Acquires Absorption Systems

CordenPharma Acquires AmbioPharm to Expand Global Peptide API Capacity

May 28, 2026

Healthcare Services

CordenPharma has entered into an agreement to acquire AmbioPharm, a U.S.-headquartered peptide API CDMO with manufacturing sites in North Augusta, South Carolina and Shanghai, China. The acquisition expands CordenPharma’s peptide API development and manufacturing capabilities, increasing U.S. capacity for purification and lyophilization and adding Shanghai-based upstream capacity.

Pharmaron Acquires 82.54% of Biortus Biosciences

October 28, 2025

Healthcare Services

Pharmaron Beijing Co., Limited has entered into a definitive Share Purchase Agreement to acquire 82.54% of Biortus Biosciences Co., Ltd. and its affiliates. The transaction is expected to close after satisfaction of customary closing conditions and is intended to strengthen Pharmaron’s structure-based drug discovery and protein science capabilities.

Alcohol Monitoring Systems, Inc. Acquires PharmChem, Inc.

July 21, 2025

Healthcare Services

PharmChem, Inc. entered into a definitive agreement to be acquired by Alcohol Monitoring Systems, Inc. Under the terms, PharmChem shareholders will receive $3.75 per share in cash. The transaction is subject to shareholder approval and customary closing conditions, and is expected to close before the end of the third quarter.

Ellab Acquires PharmaSys, Inc.

May 3, 2023

Healthcare Services

Ellab has acquired PharmaSys, Inc., a Raleigh, North Carolina-based validation and CQV services firm with 17 employees, as part of Ellab's strategy to expand its US field services in the biopharma sector. The PharmaSys owners, Nancy K. Lankford and Charles L. Lankford, will remain through the transition before retiring this summer.

Pharmacosmos A/S Acquires AbFero Pharmaceuticals, Inc.

November 11, 2021

Pharmaceuticals

Pharmacosmos A/S (Pharmacosmos Group) has agreed to acquire all assets of Boston-based clinical-stage AbFero Pharmaceuticals, Inc. under a share purchase agreement for up to $225 million including upfront, milestone, and royalty components. The acquisition adds AbFero’s SP-420 iron chelation program to Pharmacosmos’ iron-metabolism-focused R&D and commercial capabilities to accelerate development and commercialization for transfusional iron overload and related indications.

Merck to Acquire Acceleron Pharma Inc for $11.5B

September 30, 2021

Biotechnology

Merck (through a subsidiary) entered into a definitive agreement to acquire Acceleron Pharma Inc for $180 per share in cash, for an approximate total equity value of $11.5 billion. The transaction will be completed via a tender offer followed by a merger, and is expected to close in the fourth quarter of 2021, subject to conditions including regulatory approvals and tender of at least a majority of outstanding shares.